Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel
The FDA's Cellular, Tissue and Gene Therapies Advisory Committee voted 9 to 3 that available evidence did not support the effectiveness of Deramiocel for treating cardiomyopathy in Duchenne muscular dystrophy. Capricor noted the vote addressed a narrower indication than proposed and did not include a benefit-risk assessment, while highlighting the committee's supportive feedback on upper limb function data.
Key figures
- Pdufa date
- August 22, 2026
- Adcomm vote for
- 3
- Dmd prevalence us
- 15000
- Adcomm vote abstain
- 0
- Adcomm vote against
- 9
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.